Search Results 771-780 of 23459 for B cell lymphomas

  1. Acute lymphocytic leukemia - Diagnosis and treatment - Mayo Clinic

    They also look for certain changes in the cancer cells and determine whether the leukemia cells began from B lymphocytes or T lymphocytes. This information ...

  2. Medical Research & Education - Mayo Clinic News Network

    ... B-Cell Lymphoma featured image. Cancer. Everolimus R-CHOP Combination Safe for Treating Diffuse Large B-Cell Lymphoma. Joe Dangor. June 29, 2016. In the Loop ...

  3. Clinical trials - Oncology (Medical)

    1 cells administered following a conditioning lymphodepletion regimen in diffuse large B cell lymphoma (DLBCL) subjects who failed at least two lines of ...

  4. Clinical trials - Oncology (Medical)

    The purpose of this study is to provide access to CTL019 through Managed Access Program (MAP) for acute lymphoblastic leukemia (ALL) or diffuse large b-cell ...

  5. Clinical trials - Oncology (Medical)

    The purpose of this study is to provide access to CTL019 through Managed Access Program (MAP) for acute lymphoblastic leukemia (ALL) or diffuse large b-cell ...

  6. Clinical trials - Oncology (Medical)

    The purpose of this study is to provide access to CTL019 through Managed Access Program (MAP) for acute lymphoblastic leukemia (ALL) or diffuse large b-cell ...

  7. Cancer Physicians - Medical Professionals - Mayo Clinic

    James M. Foran, M.D.. Jacksonville, FL. Area of Focus: Bone marrow transplant, CAR-T cell therapy, Myelodysplastic syndromes, B-cell lymphoma, Lymphoma, ...

  8. Clinical trials - Oncology (Medical)

    The purpose of this study is to provide access to CTL019 through Managed Access Program (MAP) for acute lymphoblastic leukemia (ALL) or diffuse large b-cell ...

  9. Oncology (Medical) - Doctors - Mayo Clinic

    ogenous leukemia, Non-Hodgkin lymphoma, Hodgkin lymphoma, Follicular lymphoma, Burkitt lymphoma, B-cell lymphoma, T-cell lymphoma. Show more areas of focus ...

  10. A Study of JNJ-68284528, a Therapy Directed Against B-Cell Maturation Antigen (BCMA) in Participants with Relapsed or Refractory Multiple Myeloma - Mayo Clinic

    A Study of JNJ-68284528, a Therapy Directed Against B-Cell Maturation Antigen (BCMA) in Participants with Relapsed or Refractory Multiple Myeloma · Share ...